Curonix Announces PNS IMPACT Study Confirms Long-Term Pain Relief Benefits

POMPANO BEACH, Fla., Sept. 28, 2026 /CourierPR/ -- Curonix LLC, a leading medical technology company focused on chronic pain relief, has announced the publication of a significant study in Pain Physician, which confirms the effectiveness of its Freedom® Peripheral Nerve Stimulator (PNS) System in real-world clinical practice.

The PNS IMPACT Study, a hybrid analysis combining a single-center retrospective review of 175 Freedom PNS implanted patients with a national claims analysis of 953 patients, confirms that the benefits observed in previously published randomized controlled trials can be replicated in real-world clinical practice. The findings highlight the PNS therapy’s ability to provide sustained pain relief and reduce long-term reliance on high-risk opioid medication.

According to the study, at 24 months, subjects reported a pain reduction of 80% from baseline, and this reduction remained durable through 36 months. No serious adverse events were reported, indicating the safety and efficacy of the Freedom PNS System. The study also demonstrated a favorable downward trend in opioid use, suggesting reduced long-term reliance on high-risk opioids.

Moreover, the PNS therapy was found to minimize patient burden by reducing healthcare utilization. At 24 months, office visits and pain management interventions were reduced by 58.9% and 90%, respectively. Hospital outpatient department (HOPD) and ambulatory surgical center (ASC) visits were reduced by 35.1% and 58.8%, respectively. These reductions in healthcare encounters suggest improved long-term clinical outcomes, benefiting patients through fewer treatments, reduced treatment burden, lower healthcare expenditures, and improved functional independence.

The Freedom PNS System is a non-integrated, minimally invasive implant that does not include an implanted battery. It is powered by HF-EMC (High-Frequency Electromagnetic Coupling) and is comprised of a two-component implantable neurostimulator, an externally worn transmitter, and software used to set patient-specific stimulation programs. The two-component neurostimulator, anchored within two separate incisions, including the creation of a subcutaneous pocket, is the first and only permanent PNS system in the United States that is MR Conditional with the ability to scan throughout the body and over the implanted device at both 1.5T and 3T.

Curonix is committed to building trust through product research, data, and a continued focus on improving the lives of patients living with chronic pain. This publication reinforces Freedom PNS as a clinically supported treatment option, giving physicians greater confidence and patients added reassurance in a therapy supported by Level 1 clinical evidence, consistent safety and efficacy data, and meaningful outcomes replicated in real-world settings.